TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.390nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.440nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.780nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair